Oppenheimer Downgrades Alcobra Ltd. (ADHD) to Perform
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Oppenheimer downgraded Alcobra Ltd. (NASDAQ: ADHD) from Outperform to Perform after the FDA has informed ADHD that a full clinical hold has been placed on MDX.
Analyst Jay Olson commented, "The decision was based on pre-clinical findings and there was no human data referenced in the FDA communication according to ADHD management. ADHD will provide more details on FDA's decision once a written notification is received next week. Prior to the clinical hold, the phase 3 MEASURE study of MDX in adult ADHD was expected to reach full enrollment in 4Q16. We view this setback as a delay to commercialization of MDX with increased uncertainty around future cash requirements and we therefore downgrade ADHD to Perform and withdraw our price target."
Shares of Alcobra Ltd. closed at $4.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MoffettNathanson Downgrades AMC Networks (AMCX) to Sell
- Credit Suisse Upgrades Juniper Networks (JNPR) to Outperform
- Wedbush Raises Price Target on Francesca's (FRAN) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!